e-miRgency develops a diagnostic platform for early cancer detection and monitoring using microRNA (miRNA) biomarkers. Our technology analyzes unique miRNA expression profiles to provide precise insights into disease presence and progression, empowering healthcare providers with actionable data for timely intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer detection methods often present limitations in terms of invasiveness, cost, and sensitivity for identifying disease at its earliest, most treatable stages. This can lead to delayed diagnoses and suboptimal patient outcomes.
Solution
e-miRgency is developing a diagnostic platform that leverages microRNA (miRNA) biomarkers for enhanced cancer detection and monitoring. Our approach utilizes the unique expression profiles of miRNAs, which are indicative of cellular changes associated with oncogenesis. By analyzing these molecular signatures, our technology aims to provide earlier and more precise insights into disease presence and progression. This empowers healthcare providers with actionable data for timely intervention strategies, ultimately contributing to improved patient prognoses.
Target Audience
Our primary customers are oncology laboratories, diagnostic service providers, and clinical research institutions seeking advanced molecular diagnostic tools for cancer.
Features
- Detection of specific microRNA (miRNA) expression patterns associated with various cancer types.
- Proprietary assay development for sensitive and quantitative miRNA analysis.
- Biomarker profiling to assess disease progression and treatment response.
- Bioinformatics pipeline for data interpretation and generation of diagnostic reports.